MARTINSRIED, GERMANY -- (MARKET WIRE) -- December 20, 2006 -- MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) announced today an early expansion of its therapeutic antibody collaboration with Pfizer Inc., until the end of 2011. Under the extended agreement, Pfizer has the option to begin new therapeutic antibody projects with MorphoSys resulting in an increased level of programs to be performed within the collaboration. As a result, the potential value for MorphoSys in research funding and potential developmental milestone payments increases to more than US$ 100 million, not including royalties. Additionally, the extension triggers a one-off payment from Pfizer to MorphoSys. Further financial details were not disclosed.
